NCT06108076 is a EARLY_PHASE1 clinical trial of Ketone Monoester (KE) in Type 2 Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT06108076?

NCT06108076 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT06108076?

Interventions in NCT06108076: Ketone Monoester (KE).

What condition does NCT06108076 study?

NCT06108076 studies Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction.

Is NCT06108076 still recruiting?

NCT06108076 is currently recruiting now. Last updated 21 January 2026.

Last reviewed 2026-01-21 · How we verify

NCT06108076

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

Recruiting now EARLY_PHASE1 Last updated 21 January 2026

What this trial tests

EARLY_PHASE1 trial testing Ketone Monoester (KE) in Type 2 Diabetes in 10 participants. Currently enrolling.

Timeline

16 January 2024

Primary endpoint
31 July 2026

31 December 2026

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	16 January 2024
Primary completion	31 July 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Ketone Monoester (KE) — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →
Heart Failure, Reduced Ejection Fraction — all drugs for Heart Failure, Reduced Ejection Fraction →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

Adults 18 to 80, any sex, with Type 2 Diabetes or Heart Failure, Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond.
Sun Q, Karwi QG, Wong N, Lopaschuk GD. · · 2024 · cited 55× · PMID 39453987 · DOI 10.1093/cvr/cvae231

Verify or expand the search:

Other trials of Ketone Monoester (KE)

Trials testing the same drug.

NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT06715748 — Effects of Exogenous Ketones on Acute Changes and Recovery of the Heart Muscle After Intense Exercise. · Phase 4 · recruiting
NCT06590623 — The Effect of Acute Exogenous Oral Ketone Supplementation on Immune Cells Function and Immune Cells Histone Β-hydroxybut · NA · recruiting

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06108076 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06108076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing